6515--The STERRAD NX System

The Department of Veterans Affairs, Network Contracting Office 1, intends to award a sole source contract to Advanced Sterilization Products (ASP) for the procurement of two STERRAD NX and STERRAD 100NX hydrogen peroxide gas plasma sterilization systems at the White River Junction VA Medical Center. This action is justified under FAR 13.106-1(b)(1)(i) because ASP is the exclusive original equipment manufacturer and the only authorized source of the STERRAD platform, including its proprietary technology, firmware, software, consumables, installation, warranty services, and trade-in programs. No third-party vendors, including the identified SDVOSB reseller TrillaMed, can replicate OEM-specific benefits such as the $15,000 LCM Trade-In Program and $8,000 Trade-Out Program, which collectively reduce overall costs by $23,000 and are unavailable through any other channel. The systems being procured are direct replacements for aging units under prior purchase orders, ensuring continuity with existing sterilization workflows, validated HPGP cycles, infection control infrastructure, and clinical safety protocols. Alternate brands like STERIS V PRO, Tuttnauer PlazMax, Getinge STERICOOL, and Steelco/Belimed VS/MST series have been determined incapable of meeting the Government’s operational needs without causing significant disruptions, requiring retraining, and invalidating current validation standards. The procurement is structured as a firm-fixed-price acquisition with an estimated total value of $166,845, covering delivery, OEM installation, one-year manufacturer warranty, user manuals, technical training, and full integration support. Performance will occur at the White River Junction VA Medical Center in Vermont, with final inspection and acceptance conducted by the Government to ensure compliance with FDA regulations, VA infection control standards, and established operational benchmarks. The contract is not open for competitive bidding, but interested parties may submit a capability statement demonstrating OEM authorization from ASP by the response deadline of July 17, 2026. All submissions must prove direct authority to provide authentic STERRAD systems and associated services. The decision not to compete remains entirely at the Government’s discretion, grounded in the necessity of maintaining clinical continuity, avoiding safety risks, and achieving long-term cost efficiency through mandatory OEM trade-in programs and seamless interoperability with legacy systems. Funding is allocated under the line 405-26-3-2008-0196, and the